Key takeaways:
Mounjaro (tirzepatide) and Trulicity (dulaglutide) are both once-weekly injections for Type 2 diabetes. But they belong to different medication classes and work slightly differently in your body.
Mounjaro and Trulicity are both FDA approved to treat Type 2 diabetes in adults. But children as young as 10 can use Trulicity for diabetes. Trulicity is also approved to help lower the risk of cardiovascular problems in certain adults with Type 2 diabetes.
Mounjaro provides better blood glucose (sugar) management than Trulicity. Mounjaro can also help you lose more weight, though neither medication is approved for weight loss.
There are ways to save on Mounjaro and Trulicity. If you’re eligible, a manufacturer savings card could help you get either for as little as $25 per prescription. Patient assistance programs are also available.
If you’re living with Type 2 diabetes, you’re likely taking medication to help lower your blood glucose (sugar). Oral medications are a common starting point for many people. But it’s also common to use diabetes injections. This is especially true if your treatment goals include weight loss or heart protection.
Mounjaro (tirzepatide) and Trulicity (dulaglutide) are two popular non-insulin injections. They’re both safe and work well for Type 2 diabetes. But they have some notable differences, including how they work. Below, we’ll review five key differences to keep in mind when comparing Mounjaro versus Trulicity.
Mounjaro and Trulicity both act like natural gut hormones that help balance glucose levels and regulate appetite. But they target slightly different ones.
Mounjaro mimics two hormones:
Glucose-dependent insulinotropic polypeptide (GIP)
Glucagon-like peptide-1 (GLP-1)
Trulicity only acts like GLP-1. So that means they’re in different medication classes. Mounjaro is a dual GIP/GLP-1 receptor agonist. And Trulicity is a GLP-1 receptor agonist.
Both medications have similar actions in the body. These include:
Signaling the pancreas to release insulin when you eat
Reducing how much glucose your liver makes
Slowing the passage out food out of your stomach
Targeting areas of your brain that regulate appetite and food cravings
Because Mounjaro targets two gut hormones, it tends to have a greater effect on blood glucose and weight loss than Trulicity.
Other options: Trulicity (dulaglutide) is one of several alternatives to Mounjaro (tirzepatide).
Does Mounjaro cause weight loss? Yes, for many people, Mounjaro can lead to significant weight loss.
Cutting costs: Managing diabetes shouldn’t have to break the bank. Learn about how to save on Mounjaro, Trulicity, and more.
Mounjaro and Trulicity are once-weekly injections that are FDA-approved for Type 2 diabetes. But Mounjaro is approved for use in adults only. Trulicity can be used to manage the condition in adults and children age 10 and older.
Trulicity is also approved to lower the risk of serious cardiovascular problems in adults with Type 2 diabetes and heart disease or risks for developing heart disease. Experts are still studying if Mounjaro has heart benefits.
In studies, Mounjaro provided greater reduction of hemoglobin A1C (HbA1c or A1C) than Trulicity. Your A1C is an average of your blood glucose levels over the past 3 months.
A head-to-head clinical trial compared Mounjaro to Trulicity for Type 2 diabetes. After 1 year, those using Mounjaro had between a 2.4% and 2.8% A1C reduction, depending on the dose. Those using Trulicity had a 1.3% reduction.
Keep in mind that this study only compared the 0.75 mg dose of Trulicity to Mounjaro. Higher doses (up to 4.5 mg) weren’t included. But individual studies of Trulicity found that higher doses led to an A1C reduction of up to 1.8% at 8 months. These A1C results were maintained for another 4 months until the study ended. So it’s likely that Mounjaro would still provide greater glucose management than Trulicity, regardless of the dose.
Mounjaro and Trulicity aren’t approved for weight loss. But people using these medications tend to lose weight. And you may lose more with Mounjaro than with Trulicity.
The same clinical trial mentioned above also looked at changes in body weight. Those using Mounjaro lost an average of 12 lbs to 24 lbs during the study. Higher doses led to greater weight loss. Participants who used Trulicity lost minimal weight (about 1 lb).
Again, this study only looked at the 0.75 mg dose of Trulicity. But individual studies found that the highest Trulicity dose helped people lose an average of 10 lbs. So it can still provide a significant amount of weight loss for some people.
Good to know: The active ingredient in Mounjaro (tirzepatide) is approved for weight loss under the brand name Zepbound. The active ingredient in Trulicity (dulaglutide) isn’t approved for weight loss under any brand name.
Mounjaro and Trulicity both commonly cause gastrointestinal (GI) side effects. These include nausea, diarrhea, and constipation. But studies comparing the two found people using higher doses of Mounjaro (10 mg or 15 mg) experienced these issues more often.
Keep in mind that many people can use Mounjaro or Trulicity without major problems. GI side effects are usually most bothersome when you first start one of them. They can also be more noticeable after raising your dose. But they typically get better or go away after your body adjusts to the medication. Starting with the lowest dose and slowly raising it helps limit GI side effects.
If you’re having trouble with Mounjaro or Trulicity side effects, let your prescriber know. They may suggest a dose change. They can also provide tips to help manage these side effects until your body adjusts.
Yes. it’s possible to switch from Trulicity to Mounjaro. In fact, studies suggest making the switch can be helpful if you’re not meeting your diabetes treatment goals with Trulicity. You’ll likely experience additional A1C or body weight reduction.
Keep in mind that there’s no standard directions for how to switch between Trulicity and Mounjaro. So be sure to follow your prescriber’s instructions when it comes to what Mounjaro dosage you should start with.
There are ways to save on Mounjaro and Trulicity, which are available as brand-name medications. GoodRx can help you navigate between patient assistance programs and copay savings cards to save money on your prescription.
Save with a copay savings card. If you have commercial insurance, you may be eligible to pay as little as $25 per prescription for Mounjaro or Trulicity using a savings card from the manufacturer.
Save with patient assistance programs. If you’re uninsured or underinsured, you may be eligible for Mounjaro or Trulicity’s patient assistance programs, which offer the medications free of cost.
Mounjaro (tirzepatide) and Trulicity (dulaglutide) are two popular injections for Type 2 diabetes. While they both work well, they have some notable differences to keep in mind.
Mounjaro and Trulicity are both FDA approved to treat Type 2 diabetes in adults. But Trulicity can also treat the condition in children age 10 and older. Plus, Trulicity is approved to lower the risk of cardiovascular problems in certain adults with diabetes.
Mounjaro and Trulicity work in slightly different ways. Because of this, Mounjaro typically helps lower blood glucose (sugar) levels more than Trulicity. You’re also likely to lose more weight with Mounjaro.
Your healthcare team can tell you whether Mounjaro or Trulicity might be right for you.
American Diabetes Association. (n.d.). Decision cycle for person-centric glycemic management in Type 2 diabetes.
Eli Lilly and Company. (2023). Trulicity- dulaglutide injection, solution [package insert].
Eli Lilly and Company. (2024). Mounjaro- tirzepatide injection, solution [package insert].
Frias, J. P., et al. (2021). Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with Type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care.
Inagaki, P. N., et al. (2022). Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with Type 2 diabetes (SURPASS J-mono): A double-blind, multicentre, randomised, phase 3 trial. The Lancet Diabetes and Endocrinology.
Min, T., et al. (2020). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of Type 2 diabetes: The SURPASS clinical trials. Diabetes Therapy.
Sawamura, T., et al. (2024). Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: A retrospective study. Journal of Diabetes and Metabolic Disorders.